Baidu
map

感染

订阅

MedSci主页 / 所有栏目 / 感染

Achillion丙肝药物ACH-3102二期临床数据良好有望挑战Sovaldi

2014-08-18 佚名 生物谷

丙肝药物丙肝鸡尾酒疗法
关注

生物技术公司Achillion最近正在紧锣密鼓地进行其治疗丙肝鸡尾酒疗法ACH-3102的开发。公司最近宣布目前ACH-3102与吉利德公司的Sovaldi联合治疗二期研究数据十分理想。此次二期研究受试的18名患者在接受鸡尾酒疗法之后全部痊愈且并未观察到明显副作用。下一步研究人员计划扩大二期临床研究规模，对照组与治疗组分别额外招募6名患者，并希望于今年年底正式完成这一临床研究。此次研究的目的在于确

生物技术公司Achillion最近正在紧锣密鼓地进行其治疗丙肝鸡尾酒疗法ACH-3102的开发。公司最近宣布目前ACH-3102与吉利德公司的Sovaldi联合治疗二期研究数据十分理想。此次二期研究受试的18名患者在接受鸡尾酒疗法之后全部痊愈且并未观察到明显副作用。下一步研究人员计划扩大二期临床研究规模，对照组与治疗组分别额外招募6名患者，并希望于今年年底正式完成这一临床研究。

此次研究的目的在于确定Achillion公司开发的NS5A抗丙肝药物ACH-3102与吉利德公司的Sovaldi在不使用利巴韦林联合治疗I型基因型丙肝患者的效果。尽管目前市场上吉利德与艾伯维等公司凭借自己的特效药已经占据丙肝治疗的半壁江山，但是Achillion公司仍有机会，此前Achillion就宣称希望将丙肝治愈周期缩短为8周。

此次临床二期研究公布刺激Achillion公司股价大涨，投资者希望这一数据将有助于大型生物医药公司收购这一疗法。

版权声明：
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料，版权均属于梅斯医学所有。非经授权，任何媒体、网站或个人不得转载，授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章，或“梅斯号”自媒体发布的文章，仅系出于传递更多信息之目的，本站仅负责审核内容合规，其内容不代表本站立场，本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系，我们将立即进行删除处理。
在此留言
评论区 (6)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=2040112, encodeId=8f18204011289, content=<a href='/topic/show?id=ecf72093855' target=_blank style='color:#2F92EE;'>#丙肝药#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=66, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=20938, encryptionId=ecf72093855, topicName=丙肝药)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=322359, createdName=bioon3, createdTime=Sat Jan 24 11:19:00 CST 2015, time=2015-01-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2054755, encodeId=0e3c2054e55e1, content=<a href='/topic/show?id=82491656057' target=_blank style='color:#2F92EE;'>#Sovaldi#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=70, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=16560, encryptionId=82491656057, topicName=Sovaldi)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/DYAIOgq83eqySEUYKeYDjXJMYMrtscBNkpAnLfQZgDcdkEratcJPqS7ARJOXqllZQhCSFicErlBFbIywuoiaP0LQ/132, createdBy=012d2500132, createdName=ms5880526374914242, createdTime=Thu Aug 28 15:19:00 CST 2014, time=2014-08-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1778986, encodeId=295e1e78986f2, content=<a href='/topic/show?id=366f1852e1' target=_blank style='color:#2F92EE;'>#Achillion#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=63, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1852, encryptionId=366f1852e1, topicName=Achillion)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2ba9118, createdName=makuansheng, createdTime=Fri Feb 27 13:19:00 CST 2015, time=2015-02-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1940382, encodeId=b3461940382b0, content=<a href='/topic/show?id=3ec023929ce' target=_blank style='color:#2F92EE;'>#二期临床#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=69, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=23929, encryptionId=3ec023929ce, topicName=二期临床)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=44a360, createdName=jklm09, createdTime=Wed Dec 31 09:19:00 CST 2014, time=2014-12-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2016684, encodeId=0a0a201668493, content=<a href='/topic/show?id=75a2228481a' target=_blank style='color:#2F92EE;'>#临床数据#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=22848, encryptionId=75a2228481a, topicName=临床数据)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=fa4f352, createdName=chenlianhui, createdTime=Mon Aug 03 23:19:00 CST 2015, time=2015-08-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1469388, encodeId=d1041469388d9, content=<a href='/topic/show?id=9d6522e613' target=_blank style='color:#2F92EE;'>#ALD#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=91, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2276, encryptionId=9d6522e613, topicName=ALD)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=64f67025397, createdName=zhangjingnwpu, createdTime=Wed Aug 20 00:19:00 CST 2014, time=2014-08-20, status=1, ipAttribution=)]
    2015-01-24 bioon3

    #丙肝药#

    0

  2. [GetPortalCommentsPageByObjectIdResponse(id=2040112, encodeId=8f18204011289, content=<a href='/topic/show?id=ecf72093855' target=_blank style='color:#2F92EE;'>#丙肝药#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=66, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=20938, encryptionId=ecf72093855, topicName=丙肝药)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=322359, createdName=bioon3, createdTime=Sat Jan 24 11:19:00 CST 2015, time=2015-01-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2054755, encodeId=0e3c2054e55e1, content=<a href='/topic/show?id=82491656057' target=_blank style='color:#2F92EE;'>#Sovaldi#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=70, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=16560, encryptionId=82491656057, topicName=Sovaldi)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/DYAIOgq83eqySEUYKeYDjXJMYMrtscBNkpAnLfQZgDcdkEratcJPqS7ARJOXqllZQhCSFicErlBFbIywuoiaP0LQ/132, createdBy=012d2500132, createdName=ms5880526374914242, createdTime=Thu Aug 28 15:19:00 CST 2014, time=2014-08-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1778986, encodeId=295e1e78986f2, content=<a href='/topic/show?id=366f1852e1' target=_blank style='color:#2F92EE;'>#Achillion#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=63, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1852, encryptionId=366f1852e1, topicName=Achillion)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2ba9118, createdName=makuansheng, createdTime=Fri Feb 27 13:19:00 CST 2015, time=2015-02-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1940382, encodeId=b3461940382b0, content=<a href='/topic/show?id=3ec023929ce' target=_blank style='color:#2F92EE;'>#二期临床#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=69, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=23929, encryptionId=3ec023929ce, topicName=二期临床)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=44a360, createdName=jklm09, createdTime=Wed Dec 31 09:19:00 CST 2014, time=2014-12-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2016684, encodeId=0a0a201668493, content=<a href='/topic/show?id=75a2228481a' target=_blank style='color:#2F92EE;'>#临床数据#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=22848, encryptionId=75a2228481a, topicName=临床数据)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=fa4f352, createdName=chenlianhui, createdTime=Mon Aug 03 23:19:00 CST 2015, time=2015-08-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1469388, encodeId=d1041469388d9, content=<a href='/topic/show?id=9d6522e613' target=_blank style='color:#2F92EE;'>#ALD#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=91, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2276, encryptionId=9d6522e613, topicName=ALD)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=64f67025397, createdName=zhangjingnwpu, createdTime=Wed Aug 20 00:19:00 CST 2014, time=2014-08-20, status=1, ipAttribution=)]
    2014-08-28 ms5880526374914242

    #Sovaldi#

    0

  3. [GetPortalCommentsPageByObjectIdResponse(id=2040112, encodeId=8f18204011289, content=<a href='/topic/show?id=ecf72093855' target=_blank style='color:#2F92EE;'>#丙肝药#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=66, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=20938, encryptionId=ecf72093855, topicName=丙肝药)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=322359, createdName=bioon3, createdTime=Sat Jan 24 11:19:00 CST 2015, time=2015-01-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2054755, encodeId=0e3c2054e55e1, content=<a href='/topic/show?id=82491656057' target=_blank style='color:#2F92EE;'>#Sovaldi#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=70, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=16560, encryptionId=82491656057, topicName=Sovaldi)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/DYAIOgq83eqySEUYKeYDjXJMYMrtscBNkpAnLfQZgDcdkEratcJPqS7ARJOXqllZQhCSFicErlBFbIywuoiaP0LQ/132, createdBy=012d2500132, createdName=ms5880526374914242, createdTime=Thu Aug 28 15:19:00 CST 2014, time=2014-08-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1778986, encodeId=295e1e78986f2, content=<a href='/topic/show?id=366f1852e1' target=_blank style='color:#2F92EE;'>#Achillion#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=63, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1852, encryptionId=366f1852e1, topicName=Achillion)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2ba9118, createdName=makuansheng, createdTime=Fri Feb 27 13:19:00 CST 2015, time=2015-02-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1940382, encodeId=b3461940382b0, content=<a href='/topic/show?id=3ec023929ce' target=_blank style='color:#2F92EE;'>#二期临床#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=69, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=23929, encryptionId=3ec023929ce, topicName=二期临床)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=44a360, createdName=jklm09, createdTime=Wed Dec 31 09:19:00 CST 2014, time=2014-12-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2016684, encodeId=0a0a201668493, content=<a href='/topic/show?id=75a2228481a' target=_blank style='color:#2F92EE;'>#临床数据#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=22848, encryptionId=75a2228481a, topicName=临床数据)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=fa4f352, createdName=chenlianhui, createdTime=Mon Aug 03 23:19:00 CST 2015, time=2015-08-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1469388, encodeId=d1041469388d9, content=<a href='/topic/show?id=9d6522e613' target=_blank style='color:#2F92EE;'>#ALD#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=91, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2276, encryptionId=9d6522e613, topicName=ALD)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=64f67025397, createdName=zhangjingnwpu, createdTime=Wed Aug 20 00:19:00 CST 2014, time=2014-08-20, status=1, ipAttribution=)]
    2015-02-27 makuansheng

    #Achillion#

    0

  4. [GetPortalCommentsPageByObjectIdResponse(id=2040112, encodeId=8f18204011289, content=<a href='/topic/show?id=ecf72093855' target=_blank style='color:#2F92EE;'>#丙肝药#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=66, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=20938, encryptionId=ecf72093855, topicName=丙肝药)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=322359, createdName=bioon3, createdTime=Sat Jan 24 11:19:00 CST 2015, time=2015-01-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2054755, encodeId=0e3c2054e55e1, content=<a href='/topic/show?id=82491656057' target=_blank style='color:#2F92EE;'>#Sovaldi#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=70, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=16560, encryptionId=82491656057, topicName=Sovaldi)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/DYAIOgq83eqySEUYKeYDjXJMYMrtscBNkpAnLfQZgDcdkEratcJPqS7ARJOXqllZQhCSFicErlBFbIywuoiaP0LQ/132, createdBy=012d2500132, createdName=ms5880526374914242, createdTime=Thu Aug 28 15:19:00 CST 2014, time=2014-08-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1778986, encodeId=295e1e78986f2, content=<a href='/topic/show?id=366f1852e1' target=_blank style='color:#2F92EE;'>#Achillion#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=63, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1852, encryptionId=366f1852e1, topicName=Achillion)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2ba9118, createdName=makuansheng, createdTime=Fri Feb 27 13:19:00 CST 2015, time=2015-02-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1940382, encodeId=b3461940382b0, content=<a href='/topic/show?id=3ec023929ce' target=_blank style='color:#2F92EE;'>#二期临床#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=69, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=23929, encryptionId=3ec023929ce, topicName=二期临床)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=44a360, createdName=jklm09, createdTime=Wed Dec 31 09:19:00 CST 2014, time=2014-12-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2016684, encodeId=0a0a201668493, content=<a href='/topic/show?id=75a2228481a' target=_blank style='color:#2F92EE;'>#临床数据#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=22848, encryptionId=75a2228481a, topicName=临床数据)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=fa4f352, createdName=chenlianhui, createdTime=Mon Aug 03 23:19:00 CST 2015, time=2015-08-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1469388, encodeId=d1041469388d9, content=<a href='/topic/show?id=9d6522e613' target=_blank style='color:#2F92EE;'>#ALD#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=91, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2276, encryptionId=9d6522e613, topicName=ALD)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=64f67025397, createdName=zhangjingnwpu, createdTime=Wed Aug 20 00:19:00 CST 2014, time=2014-08-20, status=1, ipAttribution=)]
    2014-12-31 jklm09

    #二期临床#

    0

  5. [GetPortalCommentsPageByObjectIdResponse(id=2040112, encodeId=8f18204011289, content=<a href='/topic/show?id=ecf72093855' target=_blank style='color:#2F92EE;'>#丙肝药#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=66, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=20938, encryptionId=ecf72093855, topicName=丙肝药)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=322359, createdName=bioon3, createdTime=Sat Jan 24 11:19:00 CST 2015, time=2015-01-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2054755, encodeId=0e3c2054e55e1, content=<a href='/topic/show?id=82491656057' target=_blank style='color:#2F92EE;'>#Sovaldi#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=70, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=16560, encryptionId=82491656057, topicName=Sovaldi)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/DYAIOgq83eqySEUYKeYDjXJMYMrtscBNkpAnLfQZgDcdkEratcJPqS7ARJOXqllZQhCSFicErlBFbIywuoiaP0LQ/132, createdBy=012d2500132, createdName=ms5880526374914242, createdTime=Thu Aug 28 15:19:00 CST 2014, time=2014-08-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1778986, encodeId=295e1e78986f2, content=<a href='/topic/show?id=366f1852e1' target=_blank style='color:#2F92EE;'>#Achillion#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=63, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1852, encryptionId=366f1852e1, topicName=Achillion)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2ba9118, createdName=makuansheng, createdTime=Fri Feb 27 13:19:00 CST 2015, time=2015-02-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1940382, encodeId=b3461940382b0, content=<a href='/topic/show?id=3ec023929ce' target=_blank style='color:#2F92EE;'>#二期临床#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=69, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=23929, encryptionId=3ec023929ce, topicName=二期临床)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=44a360, createdName=jklm09, createdTime=Wed Dec 31 09:19:00 CST 2014, time=2014-12-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2016684, encodeId=0a0a201668493, content=<a href='/topic/show?id=75a2228481a' target=_blank style='color:#2F92EE;'>#临床数据#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=22848, encryptionId=75a2228481a, topicName=临床数据)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=fa4f352, createdName=chenlianhui, createdTime=Mon Aug 03 23:19:00 CST 2015, time=2015-08-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1469388, encodeId=d1041469388d9, content=<a href='/topic/show?id=9d6522e613' target=_blank style='color:#2F92EE;'>#ALD#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=91, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2276, encryptionId=9d6522e613, topicName=ALD)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=64f67025397, createdName=zhangjingnwpu, createdTime=Wed Aug 20 00:19:00 CST 2014, time=2014-08-20, status=1, ipAttribution=)]
    2015-08-03 chenlianhui

    #临床数据#

    0

  6. [GetPortalCommentsPageByObjectIdResponse(id=2040112, encodeId=8f18204011289, content=<a href='/topic/show?id=ecf72093855' target=_blank style='color:#2F92EE;'>#丙肝药#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=66, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=20938, encryptionId=ecf72093855, topicName=丙肝药)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=322359, createdName=bioon3, createdTime=Sat Jan 24 11:19:00 CST 2015, time=2015-01-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2054755, encodeId=0e3c2054e55e1, content=<a href='/topic/show?id=82491656057' target=_blank style='color:#2F92EE;'>#Sovaldi#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=70, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=16560, encryptionId=82491656057, topicName=Sovaldi)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/DYAIOgq83eqySEUYKeYDjXJMYMrtscBNkpAnLfQZgDcdkEratcJPqS7ARJOXqllZQhCSFicErlBFbIywuoiaP0LQ/132, createdBy=012d2500132, createdName=ms5880526374914242, createdTime=Thu Aug 28 15:19:00 CST 2014, time=2014-08-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1778986, encodeId=295e1e78986f2, content=<a href='/topic/show?id=366f1852e1' target=_blank style='color:#2F92EE;'>#Achillion#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=63, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1852, encryptionId=366f1852e1, topicName=Achillion)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2ba9118, createdName=makuansheng, createdTime=Fri Feb 27 13:19:00 CST 2015, time=2015-02-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1940382, encodeId=b3461940382b0, content=<a href='/topic/show?id=3ec023929ce' target=_blank style='color:#2F92EE;'>#二期临床#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=69, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=23929, encryptionId=3ec023929ce, topicName=二期临床)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=44a360, createdName=jklm09, createdTime=Wed Dec 31 09:19:00 CST 2014, time=2014-12-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2016684, encodeId=0a0a201668493, content=<a href='/topic/show?id=75a2228481a' target=_blank style='color:#2F92EE;'>#临床数据#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=22848, encryptionId=75a2228481a, topicName=临床数据)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=fa4f352, createdName=chenlianhui, createdTime=Mon Aug 03 23:19:00 CST 2015, time=2015-08-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1469388, encodeId=d1041469388d9, content=<a href='/topic/show?id=9d6522e613' target=_blank style='color:#2F92EE;'>#ALD#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=91, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2276, encryptionId=9d6522e613, topicName=ALD)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=64f67025397, createdName=zhangjingnwpu, createdTime=Wed Aug 20 00:19:00 CST 2014, time=2014-08-20, status=1, ipAttribution=)]
    2014-08-20 zhangjingnwpu

    #ALD#

    0

Baidu
map
Baidu
map
Baidu
map